Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Ecs Botanics Holdings Ltd ( (AU:ECS) ) is now available.
ECS Botanics Holdings Ltd has reported significant progress in its FY25 financial results, marked by a successful transition to a hybrid B2C and B2B model. Despite a slight decline in total revenue to $19.5 million, the company achieved a record full-year harvest and a 20% quarter-on-quarter increase in B2C sales, driven by its Avani and OzSun brands. ECS expanded its product portfolio and strengthened its market position, supported by protective cropping enclosures and strategic investments in scale and quality. The company also undertook a conservative reassessment of asset values, resulting in a net loss after tax of $5.7 million, but maintained a strong balance sheet with $2.9 million undrawn loan capacity, positioning it for future growth.
More about Ecs Botanics Holdings Ltd
ECS Botanics Holdings Ltd is a leading medicinal cannabis company that operates in the medicinal cannabis industry. The company focuses on both B2C and B2B models, offering a range of products including capsules, oils, pastilles, and premium flower under its Avani and OzSun brands. ECS is recognized as one of Australia’s top 15 medicinal cannabis brands, engaging over 800 prescribers and expanding its market presence in both local and European markets.
Average Trading Volume: 1,651,266
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$9.72M
For an in-depth examination of ECS stock, go to TipRanks’ Overview page.